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Summary
Background Virulent Bordetella pertussis, the causative agent of whooping cough,
exacerbates allergic airway inflammation in a murine model of ovalbumin (OVA)
sensitization. A live genetically attenuated B. pertussis mucosal vaccine, BPZE1, has been
developed that evokes full protection against virulent challenge in mice but the effect of this
attenuated strain on the development of allergic responses is unknown.
Objective To assess the influence of attenuated B. pertussis BPZE1 on OVA priming in a murine
model of allergic airway inflammation.
Methods Mice were challenged with virulent or attenuated strains of B. pertussis, and
sensitized to allergen (OVA) at the peak of bacterial carriage. Subsequently, airway
pathology, local inflammation and OVA-specific immunity were examined.
Results In contrast to virulent B. pertussis, live BPZE1 did not exacerbate but reduced the
airway pathology associated with allergen sensitization. BPZE1 immunization before allergen
sensitization did not have an adjuvant effect on allergen specific IgE but resulted in a
statistically significant decrease in airway inflammation in tissue and bronchoalveolar lavage
fluid. BPZE1 significantly reduced the levels of OVA-driven IL-4, IL-5 and IL-13 but induced a
significant increase in IFN-g in response to OVA re-stimulation.
Conclusions These data demonstrate that, unlike virulent strains, the candidate attenuated B.
pertussis vaccine BPZE1 does not exacerbate allergen-driven airway pathology. BPZE1 may
represent an attractive T-helper type 1 promoting vaccine candidate for eradication of
whooping cough that is unlikely to promote atopic disease.
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Introduction
The pathogenesis of allergic asthma remains unclear.
However, the current understanding involves the expan-
sion of CD41 T-helper type 2 (Th2) cells and a breakdown
in tolerance to otherwise innocuous environmental aller-
gens [1]. Genetic predisposition, coupled with environ-
mental influences, appear to affect the regular suppression
of Th2-mediated responses [2]. It has been hypothesized
that abnormalities in the maturation of the lung during
fetal and neonatal development may render the airways
more susceptible to environmental allergens [3], favour-
ing polarization towards the Th2 phenotype and thus,
predisposing the individual to atopy and asthma. Aller-
gen-driven production of IL-4, IL-5 and IL-13 are typical
of allergic pathologies, and the secretion of such
Th2-cytokines initiates isotype class switching of B cells
towards IgE [4], increased mucus production [5] and
recruitment of eosinophils to the airways [6, 7]. Because
CD41 Th2 cells represent a co-ordinating cell type in some
allergies, it was suggested that the induction of counter-
balancing responses might prevent the subsequent devel-
opment of atopic disease [1]. According to this
modification of Strachan’s hygiene hypothesis [8], micro-
bial exposure activates innate immune pathways that alter
Th1, Th2 and Treg responses [1]. This results in the
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suppression of Th2 cell expansion, and a consequent
inhibition of isotype switching to IgE. However, several
studies have suggested that viral and bacterial infections
play a role in exacerbation of respiratory disease. For
example, respiratory syncytial virus [9, 10] and virulent
Bordetella pertussis infection exacerbate allergic inflamma-
tion [11]. The latter has been shown to exacerbate airway
pathology [12, 13] and stimulate IgE responses in a murine
model of allergen-driven inflammation despite induction of
Th1 immunity [14, 15]. Th2-inducing acellular pertussis (Pa)
vaccines protect against B. pertussis-induced exacerbation
of allergic asthma, but induce IL-13 both at a systemic and
local level [16]. On the other hand, systemic immunization
with Th1-inducing whole-cell pertussis (Pw) vaccines in-
hibits allergic airway responsiveness [17] indicating that
protection from allergen-driven pathology is not simply
modulation of Th1/Th2 responses, but may also be asso-
ciated with the degree of airway damage at the time of
priming, such that allergen priming in the mucosae during
breakdown of the airway epithelial mesenchymal unit may
be an equally important factor.
Recently, a genetically attenuated B. pertussis strain,
BPZE1, has been developed as a live neonatal mucosal
vaccine candidate against whooping cough [18]. This
strain induces strong local and systemic immune re-
sponses upon a single intranasal delivery [18]. Adminis-
tration via the nasal route mimics natural infection and is
expected to promote long-lasting immunity in children
fromo1 month of age [19]. Although full attenuation of
BPZE1 has been extensively documented in murine mod-
els, the influence of BPZE1 administration on allergen
priming and allergen-induced pathology is not known,
but is of obvious importance in ascertaining the safety of
this live vaccine candidate.
This preclinical study compared a virulent pertussis
strain, with the candidate vaccine, BPZE1, and examined
their effect on the induction of ovalbumin (OVA)-induced
airway inflammation using previously characterized ani-
mal models. We show here that, unlike virulent strains,
attenuated BPZE1 did not exacerbate but reduced aller-
gen-driven pathology.
Materials
Immunization, sensitization and airway delivery of
ovalbumin and Bordetella pertussis
Eight- to 12-week-old, female BALB/c mice (Harlan, Oxon,
UK) were used and maintained according to the regulations
and guidelines of the Irish Department of Health, and the
Research Ethics Committee of the National University of
Ireland, Maynooth. Mice were exposed to live virulent or
attenuated bacteria, and sensitized to allergen during infec-
tion. Virulent B. pertussis BPSM [20] and attenuated BPZE1
were cultured as previously described [21]. Attenuated or
virulent strains at mid-log growth were administered to mice
by aerosol using the respiratory challenge model and stan-
dard protocols [16]. Briefly mice received set time aerosol
exposure which models natural mode of infection to achieve
a colonizing dose of 1106CFU/mouse. This dose was
chosen for three reasons, it was the optimized dose from
earlier studies [21], to be consistent with previous reports in
this model [16, 17] and because this standard version of the
respiratory challenge protocol had been used in assessment
of clinical lots of previous B. pertussis vaccines [13]. At the
peak of infection (10 days) and at 24 days, mice were
sensitized by intraperitoneal injection (0.3mL) of 100mg/mL
OVA in adjuvant (AlumImjectTM, Pierce, IL, USA). Mice were
challenged intranasally (30mL) with OVA (50mg/mL) on days
24, 35, 36 and 37. Various control groups (n= 10) received
sham delivery of sterile phosphate-buffered saline (PBS) in
place of the active agent as previously described [12].
Bronchoalveolar lavage and respiratory tract histology
On day 37, mice were killed by lethal injection of sodium
pentobarbital, and bronchoalveolar lavage fluid (BALF)
was collected [12]. Total leucocytes and differential cell
counts were performed as described [12], using Diff Quik/
Rapi-Diff IITM (Triangle Biomedical Sciences, Durham, NC,
USA). Lungs from non-lavaged mice were removed and
fixed in 10% (v/v) formalin/PBS, embedded in para-
ffin, sectioned and stained with haematoxylin/eosin, or
combined Discombes/Alcian blue and periodic acid-Schiff
(PAS) stain [12]. Histopathological changes were graded
according to an established semi-quantitative scoring
system as mild, moderate or severe [16], and are shown
for convenience in supporting information (Fig. S1).
T cell proliferation assay
Splenocytes from mice were prepared as previously de-
scribed [22] and incubated for 72 h with medium (negative
control), OVA (200 mg/mL) or concanavalin A (5 mg/mL).
Supernatants were removed after 48-h incubation for
cytokine analysis, and cultures received fresh medium.
Cells were incubated for the final 6 h with [3H]-thymidine
and proliferation was detected by liquid scintillation [23].
Measurement of cytokines and antibody responses
IL-5, IL-10, IL-13 and IFN-g from BALF and splenocyte
supernatants were analysed by flow cytometry (Becton-
Dickinson, Franklin Lakes, NJ, USA), using Cytometric
Bead Array Flex Sets (BD Biosciences) according to the
manufacturer’s instructions. Standard curves and raw
data were generated for each cytokine using FCAP Array
v1.0.1 software (BD Biosciences). OVA-specific serum IgE
was measured by ELISA as previously described [24] using
a rat anti-mouse IgE monoclonal antibody (BD
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Pharmingen, San Diego, CA, USA). IgE concentration was
expressed as mg/mL after comparison with murine IgE
standards (BD Pharmingen).
Statistical analysis
Values for all measurements were expressed as the mean
 standard error of the mean. Statistical analysis was
performed using GraphPad PrismTM software (GraphPad,
San Diego, CA, USA). Comparison was made using the
Kruskal–Wallis test, or the Mann–Whitney test as appro-
priate. Significance was denoted by P-valueo0.05.
Results
Attenuated Bordetella pertussis BPZE1 prevents
ovalbumin-driven allergic airway pathology
Virulent B. pertussis can exaggerate unrelated allergen
priming in animal models [12] and has been associated
with exacerbation of allergy in humans [11]. To assess the
influence of the candidate vaccine on OVA-induced airway
pathology, mice were challenged with either virulent
BPSM, or attenuated BPZE1, and sensitized to OVA at the
peak of bacterial carriage (a model previously shown to
uncover the influence of infection on allergen-driven
inflammation) [12, 13, 16]. In the absence of infection,
OVA-sensitized mice exhibited typical peribronchial and
perivascular inflammation at day 38, which was not
observed in control mice (Figs 1a and b). At this time-
point, pathology due to virulent bacterial infection alone
has resolved [22]. Priming at the peak of virulent
B. pertussis infection resulted in a more severe pathology
when compared with non-infected sensitized mice, dis-
playing strong perivascular inflammation and hypertro-
phied bronchiolar epithelium (Fig. 1c). In contrast, prior
challenge with attenuated BPZE1 resulted in decreased
peribronchial inflammation when compared with sensi-
tized, BPSM-infected mice (Fig. 1d). Excessive mucus
secretion from goblet cells is a characteristic feature of
the allergic airway. An examination of lung tissues stained
with PAS and Alcian blue demonstrated that prior immu-
nization with BPZE1 in OVA-sensitized mice reduced
mucus secretion when compared with those sensitized to
OVA alone (Fig. 2). In contrast, virulent BPSM-infection
exacerbated goblet cell hyperplasia and mucus secretion in
OVA-sensitized mice (Fig. 2c). Consistent with these data
were physiological observations of airway hyper-respon-
siveness (AHR) suggesting that prior immunization with
BPZE1 resulted in significantly reduced bronchial hyper-
reactivity compared with mice primed while infected with
virulent B. pertussis (supporting information Fig. S2).
Taken together these data show that unlike infection
with virulent B. pertussis, administration of attenuated
Fig. 1. Attenuated Bordetella pertussis BPZE1 reduces the severity of airway pathology induced by sensitizing allergen. Representative morphological
changes at 38 days in bronchiolar transverse sections of lungs from (a) non-sensitized, (b) ovalbumin (OVA)-sensitized, (c) OVA-sensitized and infected
with B. pertussis, (d) OVA-sensitized and immunized with BPZE1. Airway inflammation was detected using haematoxylin and eosin staining of fixed
lung sections. p and h indicate perivascular inflammation and bronchiolar epithelial hypertrophy, respectively. All images are representative of multiple
sections from five mice per experiment, repeated at least twice (i.e. n410). Original magnification a–d 400.
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B. pertussis BPZE1 did not enhance, but reduced the
pathology associated with allergen sensitization.
Attenuated Bordetella pertussis BPZE1 prevents
ovalbumin-driven allergic airway inflammation
The capacity for live attenuated B. pertussis BPZE1 to
influence OVA-induced inflammatory influx to the re-
spiratory tract was examined. OVA sensitization resulted
in characteristic inflammation with eosinophils, neutro-
phils, macrophages and lymphocytes detected in BALF
not seen in control mice (Fig. 3). Mice sensitized during
virulent B. pertussis infection showed a similar pattern of
inflammation. However, in marked contrast, immuniza-
tion with live attenuated BPZE1 before OVA sensitization
resulted in significantly reduced inflammatory infiltration
of the airways (Po0.05) for all cells examined. Thus a
major finding of this study was that attenuated B. pertus-
sis BPZE1 reduced OVA-driven allergic airway inflamma-
tion typically seen in this model.
Bordetella pertussis BPZE1 does not enhance serum
immunoglobulin E responses to sensitizing allergen
B. pertussis is a known adjuvant for IgE, as is active
pertussis toxin [14, 15]. Therefore the influence of BPZE1
on allergic sensitization was examined by measuring the
concentration of OVA-specific IgE in serum in these mice.
Unlike non-sensitized controls, OVA sensitization induced
significant levels of IgE as expected (Fig. 4). Allergen-
specific IgE responses in mice exposed to attenuated
BPZE1 before OVA sensitization were not enhanced but
were not significantly different to those receiving OVA
alone. However, compared with mice infected with viru-
lent BPSM in combination with OVA sensitization, atte-
nuated BPZE1 immunization resulted in a significant
reduction (Po0.05) of OVA-induced IgE (Fig. 4). There-
fore, unlike virulent B. pertussis BPSM which damages
the airways, live attenuated B. pertussis BPZE1 delivered
before allergen priming did not enhance or have an
adjuvant effect upon the IgE response to allergen.
Bordetella pertussis BPZE1 modulates recall cytokine
responses to sensitizing allergen
Attenuated BPZE1 has a radically different effect on
allergen-driven airway pathology to virulent B. pertussis.
To further investigate this, the influence of bacterial
exposure on the pattern of allergen-induced cellular
immune responses was characterized. OVA-specific cyto-
kine production in both spleen cell preparations and BALF
was assessed in the groups described above, in order to
evaluate the influence of BPZE1 on allergen-induced
priming. As expected, OVA sensitization alone induced
Fig. 2. Attenuated Bordetella pertussis BPZE1 reduces the severity of mucus hyperplasia to sensitizing allergen. Representative morphological changes
at 38 days in transverse sections of bronchioles from (a) non-sensitized, (b) ovalbumin (OVA)-sensitized, (c) OVA-sensitized and infected with virulent
B. pertussis, (d) OVA-sensitized and vaccinated with BPZE1. Airway inflammation was detected using combined Discombes/Alcian blue/ periodic acid-
Schiff staining on lung sections. g and m indicate goblet cell hyperplasia and mucus secretion, respectively. All images are representative of multiple
sections from five mice per experiment repeated at least twice (i.e. n410). Original magnification 100.
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high levels of the Th2 cytokines IL-4, IL-5 and IL-13 (Fig.
5). Neither virulent BPSM nor attenuated BPZE1 alone
induced any recall response to OVA, but both provoked
strong Th1 responses to B. pertussis antigens (data not
shown), as previously reported [16]. Virulent BPSM chal-
lenge before sensitization did not induce a significant
reduction in OVA-specific IL-5 or IL-13 and did not
increase IFN-g significantly (Fig. 5). However, a striking
increase in IL-4 in BALF was observed when compared
with those sensitized to OVA alone. In contrast, BPZE1
modulated the allergen response. Prior BPZE1 signifi-
cantly reduced the levels of OVA-induced IL-5
(Po0.005), IL-13 (Po0.05) and IL-4 (Po0.005). This was
an immunomodulatory effect because suppression was
not global; BPZE1 significantly increased IFN-g in BALF
and from splenocytes re-stimulated with OVA (Po0.05).
In summary, BPZE1 did not promote Th2 cytokine induc-
tion to allergen, but rather redirected this to a Th1-like
response.
Discussion
The present study combined murine infection and sensiti-
zation models to demonstrate that an attenuated strain of
Fig. 3. Attenuated Bordetella pertussis BPZE1 reduces the cell infiltrate of bronchoalveolar lavage fluid (BALF). Effect of virulent BPSM infection,
attenuated BPZE1 challenge and/or ovalbumin (OVA) sensitization on BALF composition 24 h after final OVA exposure. Negative controls were sham
infected/sensitized with saline. BALF was examined for the total cell number (a), or the presence of neutrophils (b), eosinophils (c) or lymphocytes (d).
The data are representative of triplicate measurements from at least five animals and repeated twice. Results are expressed as mean standard error of
the mean of cell number. Po0.05.
Fig. 4. Attenuated Bordetella pertussis BPZE1 reduces allergen-induced
IgE. Ovalbumin (OVA)-specific IgE in serum elicited in response to
OVA sensitization. Sera were collected on day 38 and OVA-specific
serum IgE levels were measured by ELISA. The data presented are
representative of two experiments; in each case, at least five animals
were assessed, and each individual assessment was performed in tripli-
cate. Concentrations below 100 pg/mL were considered negative. Results
are expressed as mean antibody concentrations  standard error of the
mean. Po0.05.
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B. pertussis, BPZE1, did not enhance but reduced
allergen-driven airway pathology. BPZE1 prevented
OVA-driven inflammation of the airways, assessed by
histological and qualitative analysis of mucus production.
Furthermore, BPZE1 diminished the severity of allergen-
driven inflammation in the lungs. Eosinophilic and
neutrophilic infiltration was significantly reduced in
BPZE1-immunized mice sensitized to OVA. Virulent
BPSM enhanced IL-4 in BALF, whereas BPZE1 modulated
allergen responses towards a Th1 phenotype, demon-
strated by a marked increase in IFN-g. Likewise, analysis
of recall responses to allergen showed that BPZE1 modu-
lated responses away from IL-5 and IL-13 towards IFN-g.
In contrast to virulent B. pertussis, BPZE1 demonstrated
no adjuvant associated increase in allergen-specific IgE.
Taken together, these data demonstrate that attenuated
BPZE1 acts as a powerful immunomodulator that sup-
presses allergen-driven pathology at both a local and
systemic level.
Some versions of the hygiene hypothesis suggest that
Th1-inducing infections may have an inhibitory effect on
the development of atopy [25]. However, previous studies
have demonstrated that virulent B. pertussis enhanced the
severity of airway pathology [12, 13] despite induction of
Th1 immunity. In contrast, systemic immunization with a
Th1-inducing Pw vaccine inhibited allergic airway re-
sponsiveness [13]. These seemingly counter-intuitive
findings suggest that protection from allergen-driven
pathology is linked not just to CD41 T cell profile, but
also to the degree of airway damage at the time of priming
[14]. This can be probed using virulent (airway damaging)
and attenuated (non-damaging) bacterial strains. The
present study supports those findings showing that prior
immunization with BPZE1 that does not damage the
airway epithelium [26] resulting in significantly reduced
allergic pathology, compared with those mice sensitized
while infected with virulent B. pertussis that induces
airway damage [26]. Vaccination with Pw has been
reported to protect against B. pertussis exacerbation of
OVA-induced AHR in a murine model of allergic airway
inflammation [17] and it has been shown that there is no
allergy-promoting effect in response to common child-
hood vaccines, including pertussis vaccines [27]. How-
ever, much less is known about protective effects of
childhood vaccines against atopy, others have shown that
live attenuated vaccines, such as oral poliomyelitis vac-
cine or Bacillus–Calmette–Gue´rin, inhibited the develop-
ment of asthma and allergic disease [28]. However, the
mechanisms underlying the beneficial influence of atte-
nuated BPZE1 on allergen-driven pathology may be
multiple and inter-linked. It is known in other models that
immune interaction between infection and allergen sensi-
tization critically depends on timing of challenges [29]. In
this model, the challenge schedule was chosen to examine
the effect of prior immunization on allergen sensitization
and for consistency with previous reports [12, 16, 17].
However, it will be important to examine the reverse
scenario to assess the effect of immunization on pre-
existing allergen sensitivity, such as that seen using
unmethylated CpG oligodeoxynucleotides which inhib-
ited ragweed allergen induced lung inflammation in pre-
sensitized animals [30].
Pathology in the OVA model is driven by Th2 cytokines,
in particular IL-5 and IL-13. However, there are two
Fig. 5. Cell-mediated immune responses from splenocytes to ovalbumin (OVA) and in bronchoalveolar lavage fluid, elicited by OVA sensitization 10
days following prior exposure to attenuated (BPZE1) or virulent (BPSM) Bordetella pertussis infection. Negative symbols indicate sham sensitization or
challenge with phosphate-buffered saline. Cytokine responses from similar cultures are shown for (a) IL-5, (b) IL-13, (c) IFN-g. Responses are
representative of duplicate experiments, each of which were determined independently from at least five mice per group in each case and are expressed
as meansstandard error of the mean. Po0.05, Po0.005, Po0.0005.
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components to this; the first is the induction of IgE [31,
32] and classical atopic inflammation. The second is Th2-
driven fibrosis/remodelling [33], which can be antago-
nized by IFN-g [34, 35]. The observations here that
allergen-specific IgE was not significantly changed while
pathology was reduced in mice immunized with BPZE1
before OVA sensitization (Figs 1 and 4) suggest that a
mechanism of protection other than IgE reduction is
involved here. The inhibition of allergic airway pathology
might be explained by the modulation of the key cyto-
kines involved in remodelling. This study demonstrated
that BPZE1 shifted systemic immune responses to OVA
away from IL-4, IL-5 and IL-13 towards IFN-g. Both IL-4
and IL-5 contribute to tissue damage and remodelling due
to their function as mediators of eosinophil recruitment
[36, 37]. Infection with virulent B. pertussis exaggerates
the OVA-induced inflammatory influx to the respiratory
tract, with an increase in eosinophils (Fig. 3c), and an
associated increase in the severity of airway pathology
(Fig. 1e). Conversely, administration of attenuated BPZE1
before allergen sensitization significantly reduced inflam-
matory infiltration (Fig. 3). Airway mucus hypersecretion
is in part driven by IL-13 and is a major pathophysiologi-
cal feature of both allergic asthma [38] and whooping
cough [39]. Therefore, it is not surprising that mucus
production mirrored IL-13 levels in this study and was
significantly reduced in sensitized mice previously ex-
posed to BPZE1 (Fig. 5c). Taken together, these data
suggest that immune modulation in this model has its
greatest impact on mucus secretion and remodelling
rather than IgE induction. Since attenuation of BPZE1 is
based on the genetic removal or attenuation of three
major toxins, pertussis toxin, tracheal cytotoxin and
dermonecrotic toxin [18], this study suggests that one, or
a combination, of the attenuated virulence factors in
BPZE1 plays a role in the adjuvant effect observed with
virulent B. pertussis strains. The key finding here is that in
contrast to virulent B. pertussis, attenuated BPZE1 did not
exacerbate allergen-induced airway pathology in a mur-
ine model.
BPZE1 has been developed as a new candidate for use as
a live, intranasal, single-dose neonatal vaccine against
whooping cough [18]. Most current vaccination regimes
require three doses, beginning at 2 months of age necessi-
tating 6 months for optimal protection [40]. Therefore,
there is a need for vaccines that induce strong protection
against B. pertussis in neonates. The data presented here
support the use of this candidate vaccine even for popula-
tions where exposure to allergens and atopy is prevalent.
Allergic airway inflammation is not simply a balance
between Th1 and Th2 responses [41]. It might be that the
key beneficial feature of BPZE1 is the combination of a
Th1 skewed response, combined with the absence of
induced airway pathology. This is supported by previous
reports in which exacerbation of airway pathology to
allergen was associated with allergen priming during a
period of airway damage or remodelling [12, 42, 43]. This
combined benefit makes BPZE1 an attractive candidate as
a neonatal vaccine against whooping cough.
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Additional supporting information may be found in the
online version of this article:
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Figure S1. H&E-stained lung sections. Original magni-
fication 100. Perivascular and peribronchial inflamma-
tion was evaluated as (a) mild, (b) moderate, and (c) severe.
(a) Mild peribronchial inflammation (centre) surrounded
by clear alveoli and cross-sectioned bronchioles (bottom
left, right). (b) Moderate peribronchial inflammation sur-
rounding bronchiole (top right, bottom right) and moder-
ate alveolar inflammation. (c) Severe perivascular and
peribronchial inflammation with bronchial epithelial hy-
pertrophy (centre, centre right). Images represent typical
pathology at each grade.
Figure S2. BPZE1 challenge prior to OVA sensitisation
decreases airway hyperresponsiveness to sensitising aller-
gen. Airway responsiveness was assessed on day 37 by
methacholine induced airflow obstruction from conscious
mice using whole-body plethysmography in conjunction
with the BioSystem XA software (Buxco Electronics,
USA) as previously described [16]. (a) Non-sensitised ( ),
OVA-sensitised ( ), BPSM infected1OVA sensitisation
( ) and BPZE1 challenge1OVA sensitisation ( ). (b) Non-
sensitised (Control ), OVA-sensitised ( ), non-sensitised
BPSM infected ( ) and nonsensitised BPZE1 challenge ( ).
Results are expressed as mean enhanced pause
(PenH)S.E.M. Where no error bars are visible, error bars
are shorter than the size of the data point symbol. Data
points represent the mean PenH from eight mice in this case.
Please note: Wiley-Blackwell is not responsible for the
content or functionality of any supporting materials
supplied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
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